Minerva Neurosciences | NERV - PE Price to Earnings


Minerva Neurosciences reported 14.32 in PE Price to Earnings for its fiscal quarter ending in March of 2021.





Pe Change Date
Acadia Pharmaceuticals 9.52 1.81 Sep/2026
Adma Biologics 12.28 2.74 Jun/2026
ALKERMES 262.4 126.59 Sep/2026
AstraZeneca 24.63 0.71 Sep/2026
BioCryst Pharmaceuticals 6.84 0.78 Jun/2026
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Cipla 38.39 2.57 Sep/2026
Clal Biotechnology 11.67 2.62 Dec/2022
Compugen 5.58 0.12 Jun/2026
CSL 16.16 9.59 Dec/2025
Eli Lilly 64.5 31.61 Sep/2026
GlaxoSmithKline 9.72 0.9 Sep/2026
Grifols 11.2 1.08 Dec/2025
Halozyme Therapeutics 16.12 3.61 Sep/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
J&J 25.86 3.57 Sep/2026
Merck 34.36 2.11 Sep/2026
Neurocrine Biosciences 83.17 61.07 Sep/2026
Novartis 19.17 3.24 Sep/2026
Novavax 2.01 1.07 Dec/2025
Pfizer 15.2 3.72 Sep/2026
Roche Holding 16.48 0.39 Jun/2026
Sanofi 22.34 3.38 Sep/2026
Takeda 21.04 3.36 Sep/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023